Bisantrene is under clinical development by Race Oncology and currently in Phase II for Refractory Acute Myeloid Leukemia.

Vactosertib is under clinical development by MedPacto and currently in Phase I for Refractory Acute Myeloid Leukemia.

Hemogenyx Pharmaceuticals Opens First Clinical Site for HG-CT-1 Phase I Trial Patient Recruitment Begins for CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia in Adults ...

With cancer therapies and TALEN-based gene editing, Cellectis is projected to hit an average target price of $7.00, offering ...

A community has rallied round to show 'phenomenal' support to the family of a little girl who is in hospital with cancer.

A Sussex dentist has launched a campaign to encourage more people to sign up to the stem cell register after her brother's ...

PhD portal How many problems can IDH inhibitors solve in acute myeloid leukemia? Junshi/Impact PARP inhibitor senaparib: creating the best new drug of its kind with "synthetic lethality" UCB's new ...

Five card Charlie pays 5 to 1 FDA grants fast track designation to new PD-1 drug Balstilimab for the treatment of cervical cancer Tedizolid, azacytidine, and venetoclax combination shows promise in ...

winzo minimum withdrawal Complete remission rate is 62%; Phase 2 clinical results of innovative therapy for acute myeloid leukemia are positive Fosun Pharma Holdings subsidiary receives pharmaceutical ...

Ellissa was diagnosed with acute myeloid leukaemia - a cancer of the myeloid line of blood cells, characterised by the rapid ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...